418 related articles for article (PubMed ID: 32514765)
1. Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study.
Shin A; Park EH; Dong YH; Ha YJ; Lee YJ; Lee EB; Song YW; Kang EH
Osteoporos Int; 2020 Nov; 31(11):2131-2139. PubMed ID: 32514765
[TBL] [Abstract][Full Text] [Related]
2. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
[TBL] [Abstract][Full Text] [Related]
3. Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study.
Kim SC; Pawar A; Desai RJ; Solomon DH; Gale S; Bao M; Sarsour K; Schneeweiss S
Semin Arthritis Rheum; 2019 Oct; 49(2):222-228. PubMed ID: 30967248
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study.
Kim SC; Solomon DH; Rogers JR; Gale S; Klearman M; Sarsour K; Schneeweiss S
Arthritis Rheumatol; 2017 Jun; 69(6):1154-1164. PubMed ID: 28245350
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease.
Jin Y; Kang EH; Brill G; Desai RJ; Kim SC
J Rheumatol; 2018 Aug; 45(9):1240-1248. PubMed ID: 29764964
[TBL] [Abstract][Full Text] [Related]
6. Risk of Hospitalized Infection and Initiation of Abatacept Versus Tumor Necrosis Factor Inhibitors Among Patients With Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study.
Chen SK; Liao KP; Liu J; Kim SC
Arthritis Care Res (Hoboken); 2020 Jan; 72(1):9-17. PubMed ID: 30570833
[TBL] [Abstract][Full Text] [Related]
7. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.
Harrold LR; Reed GW; Solomon DH; Curtis JR; Liu M; Greenberg JD; Kremer JM
Arthritis Res Ther; 2016 Dec; 18(1):280. PubMed ID: 27906048
[TBL] [Abstract][Full Text] [Related]
9. Comparison of infection-related hospitalization risk and costs in tumor necrosis factor inhibitor-experienced patients with rheumatoid arthritis (RA) treated with abatacept or other targeted disease-modifying anti-rheumatic drugs (tDMARDs).
Paul D; Patil D; McDonald L; Patel V; Lobo F
J Med Econ; 2020 Sep; 23(9):1025-1031. PubMed ID: 32427547
[No Abstract] [Full Text] [Related]
10. Risk of exacerbation of pulmonary comorbidities in patients with rheumatoid arthritis after initiation of abatacept versus TNF inhibitors: A cohort study.
Kang EH; Jin Y; Desai RJ; Liu J; Sparks JA; Kim SC
Semin Arthritis Rheum; 2020 Jun; 50(3):401-408. PubMed ID: 31813561
[TBL] [Abstract][Full Text] [Related]
11. The risk of serious infection in rheumatoid arthritis patients receiving tocilizumab compared with tumor necrosis factor inhibitors in Korea.
Jeon HL; Kim SC; Park SH; Shin JY
Semin Arthritis Rheum; 2021 Oct; 51(5):989-995. PubMed ID: 34403814
[TBL] [Abstract][Full Text] [Related]
12. Infectious risk of add-on leflunomide or tacrolimus versus TNF inhibitors among patients with rheumatoid arthritis receiving background methotrexate: A population-based cohort study.
Shin A; Lee JH; Ha YJ; Lee YJ; Lee EB; Kang EH
Semin Arthritis Rheum; 2022 Aug; 55():152019. PubMed ID: 35567808
[TBL] [Abstract][Full Text] [Related]
13. Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study.
Kang EH; Jin Y; Brill G; Lewey J; Patorno E; Desai RJ; Kim SC
J Am Heart Assoc; 2018 Jan; 7(3):. PubMed ID: 29367417
[TBL] [Abstract][Full Text] [Related]
14. Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.
Xie F; Yun H; Bernatsky S; Curtis JR
Arthritis Rheumatol; 2016 Nov; 68(11):2612-2617. PubMed ID: 27213279
[TBL] [Abstract][Full Text] [Related]
15. Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study.
Choi SR; Shin A; Ha YJ; Lee YJ; Lee EB; Kang EH
Arthritis Res Ther; 2023 Jul; 25(1):129. PubMed ID: 37495973
[TBL] [Abstract][Full Text] [Related]
16. Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Singh S; Fumery M; Singh AG; Singh N; Prokop LJ; Dulai PS; Sandborn WJ; Curtis JR
Arthritis Care Res (Hoboken); 2020 Apr; 72(4):561-576. PubMed ID: 30875456
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive.
Harrold LR; Wittstock K; Kelly S; Han X; Zhuo J; Schrader A; Middaugh N; Moore PC; Khaychuk V
Adv Rheumatol; 2024 Jan; 64(1):10. PubMed ID: 38243281
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry.
Harrold LR; Litman HJ; Connolly SE; Alemao E; Kelly S; Rebello S; Hua W; Kremer JM
Rheumatol Ther; 2019 Jun; 6(2):217-230. PubMed ID: 30868550
[TBL] [Abstract][Full Text] [Related]
19. Risk of Serious Infection Among Initiators of Tumor Necrosis Factor Inhibitors Plus Methotrexate Versus Triple Therapy for Rheumatoid Arthritis: A Cohort Study.
Kang EH; Jin Y; Tong AY; Desai RJ; Kim SC
Arthritis Care Res (Hoboken); 2020 Oct; 72(10):1383-1391. PubMed ID: 31376333
[TBL] [Abstract][Full Text] [Related]
20. Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study.
Harrold LR; Litman HJ; Connolly SE; Kelly S; Hua W; Alemao E; Rosenblatt L; Rebello S; Kremer JM
J Rheumatol; 2018 Jan; 45(1):32-39. PubMed ID: 29093151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]